Northwire Canada EditionSaturday, November 7, 2026
Sign inSubscribe
Northwire
⌕
Gold 4,079.60 −0.8% Silver 51.94 −0.8% Copper 6.24 −0.5% Oil 90.83 +0.3% Palladium 1,017.10 −2.6% KRN 0.260 −7.1% GSKR 2.84 +5.6% ADE 0.125 +4.2% NRM 0.055 +0.0% BBB 0.520 −1.9% LGD 2.09 +1.9% DEC 0.110 +0.0% LCE 0.200 +0.0% NILI 0.515 −1.0% CDE 21.85 +6.7% CAN 0.045 +0.0% LORD 0.100 +0.0% HBM 29.49 +2.3% ELEF 0.265 +120.8% MUN 0.300 +0.0% SAGA 0.400 +6.7% Gold 4,079.60 −0.8% Silver 51.94 −0.8% Copper 6.24 −0.5% Oil 90.83 +0.3% Palladium 1,017.10 −2.6% KRN 0.260 −7.1% GSKR 2.84 +5.6% ADE 0.125 +4.2% NRM 0.055 +0.0% BBB 0.520 −1.9% LGD 2.09 +1.9% DEC 0.110 +0.0% LCE 0.200 +0.0% NILI 0.515 −1.0% CDE 21.85 +6.7% CAN 0.045 +0.0% LORD 0.100 +0.0% HBM 29.49 +2.3% ELEF 0.265 +120.8% MUN 0.300 +0.0% SAGA 0.400 +6.7%
Production / Operations

PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides

PharmaTher Seeks Regulatory Tailwinds Amidst Price Slump

By The Northwire Desk — AI Analysis Apr 20, 2026 · 08:01 PHRM · 0.075 PharmaTher Holdings Ltd.
Executive Summary
  • The most recent release (April 20, 2026) positions PharmaTher's PatchPrint™ and PharmaPatch™ platforms to capitalize on U.S. regulatory shifts in psychedelics and peptides.
  • Key catalysts include a new Executive Order signed by President Trump to fast-track psychedelic research and potential FDA reclassification of therapeutic peptides (Category 1).
  • The company reports positive research results for psilocybin, LSD, DMT, MDMA patches and completed an IND-enabling study for its ketamine patch.
  • Peptide candidates identified include BPC-157, GHK-Cu, TB-500, and KPV, supported by provisional patent application No. 64/034,315 filed April 13, 2026.
  • The PatchPrint™ manufacturing platform is an automated tabletop microneedle patch 3D printer targeting compounding pharmacies and hospitals.
  • This follows a series of similar announcements in March and early April 2026 regarding the same peptide and psychedelic expansion strategies.
Material Impact
  • Rating Justification: The news reinforces existing strategic narratives established over the past three months (March-April 2026) rather than introducing new financial milestones or partnerships.
  • Regulatory Catalysts: While the Executive Order is a significant regulatory development, it aligns with previous FDA/HHS discussions mentioned in April 16 news; no immediate revenue impact is quantified.
  • Market Reaction Context: The stock price has declined significantly from $0.57 (August 2025) to $0.08 (April 2026), indicating market skepticism regarding the monetization of these regulatory tailwinds despite positive announcements.
  • Financial Reality: No new capital raised or specific partnership deal closed in this release; revenue drivers remain theoretical (licensing, system placements).
  • Conclusion: The information is positive but expected given the company's stated roadmap; it does not materially alter the risk profile or valuation immediately.
PHRM · Price
Company Overview
  • Company: PharmaTher Holdings Ltd., focused on microneedle patch technology and pharmaceutical manufacturing platforms.
  • Flagship Project: PharmaPatch™ (microneedle patch product platform) and PatchPrint™ (automated tabletop 3D printer for patches).
  • Key Programs: Ketamine (generic ANDA sold, proprietary LAI retained), Psychedelics (psilocybin, LSD, MDMA), Peptides (BPC-157, GLP-1), Parkinson's Disease (LID-PD Phase 3 ready).
  • Development Stage: Early-stage R&D for patches and peptides; late-stage planning for Parkinson's disease program.
  • Manufacturing: Proprietary automated dispensing and packaging system targeting compounding pharmacies and hospitals.
Read the original news release →

More from PharmaTher Holdings Ltd.

May 27, 2026 · 08:01

PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines

Other May 13, 2026 · 10:12

PharmaTher Explores Hantavirus Treatment Amidst Stock Plunge and Strategic Pivots

Other May 13, 2026 · 10:08

PharmaTher Advances Antiviral Pipeline with Hantavirus Candidate Amidst Ketamine Monetization

Other Apr 21, 2026 · 08:01

Strategic Alignment with Federal Psychedelic Mandate

Regulatory Apr 16, 2026 · 08:01

PharmaTher Peptide Strategy Faces Regulatory Hurdles Amidst 89% Stock Decline

Regulatory Apr 13, 2026 · 08:01

PharmaTher Files Peptide Patch Patent as Stock Nears All-Time Lows Despite Pipeline Expansion

M&A / Property